|1.||Wilson, William R: 20 articles (09/2015 - 07/2007)|
|2.||Patterson, Adam V: 12 articles (03/2014 - 07/2007)|
|3.||Gu, Yongchuan: 10 articles (05/2014 - 07/2007)|
|4.||Guise, Christopher P: 7 articles (03/2014 - 05/2009)|
|5.||Patel, Kashyap: 6 articles (01/2013 - 07/2007)|
|6.||Hicks, Kevin O: 5 articles (01/2013 - 07/2007)|
|7.||Abbattista, Maria R: 4 articles (01/2013 - 02/2010)|
|8.||Pruijn, Frederik B: 3 articles (05/2014 - 10/2007)|
|9.||Pullen, Susan M: 3 articles (03/2014 - 07/2007)|
|10.||Su, Jiechuang: 3 articles (12/2013 - 01/2012)|
06/01/2011 - "In conclusion, PR-104A is glucuronidated by UGT2B7 with high specificity and seems to make a major contribution to clearance of PR-104A in humans, but it also has the potential to confer resistance in some human tumors."
03/01/2011 - "Pharmacokinetic studies identified extensive non-tumor reduction of PR-104A to the 5-amine PR-104H (identity of which was confirmed by chemical synthesis), especially in liver. "
01/01/2012 - "An anti-POR monoclonal antibody was used to probe expression using human tissue microarrays; 13 of 19 cancer types expressed detectable POR with 21% of cores (185 of 874) staining positive; this heterogeneity suggests that POR is a useful biomarker for PR-104A activation. "
02/15/2010 - "A survey of normal tissue AKR1C3 expression suggests the potential for tumor-selective PR-104A activation by this mechanism. "
03/01/2010 - "The area under the PR-104A plasma concentration-time curve at this dose exceeded that required for activity in human tumor cell cultures and xenograft models. "
12/27/2013 - "Clonogenic cell killing and reductive metabolism of PR-104A and SN30000 under anoxia also showed little change in the POR knock-outs. "
05/01/2011 - "A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity."
06/01/2009 - "This expression increased hypoxic metabolism of PR-104A to PR-104H and PR-104M as well as hypoxia-selective cytotoxicity of PR-104A and its dependence on HRR. "
07/01/2007 - "The cytotoxicity of PR-104A was increased 10- to 100-fold by hypoxia in vitro. "
05/15/2013 - "This reductase profile is similar to that for the dinitrobenzamide prodrug PR-104A under hypoxia, and fluorogenic metabolism of FSL-61 correlated significantly with PR-104A activation in a panel of 22 human tumour cell lines. "
|4.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
09/03/2015 - "Testing leukemic blasts from 11 patients confirmed that T-ALL cells were more sensitive than BCP-ALL to PR-104A in vitro, and that sensitivity correlated with AKR1C3 expression. "
03/01/2014 - "In short term cultures from patient-derived paediatric ALL xenografts, PR-104A was more potent in T-ALL than B-ALL lines, and PR-104A cytotoxicity was significantly inhibited by SN34037 in T-ALL but not B-ALL. "
|3.||Mechlorethamine (Nitrogen Mustard)
|4.||DNA (Deoxyribonucleic Acid)
|7.||tirapazamine (SR 4233)
|10.||Green S (green 5)
|1.||Heterologous Transplantation (Xenotransplantation)